

WEST Search History

08/9/02 407

AH # 41

DATE: Monday, June 24, 2002

Set Name Query
side by sideHit Count Set Name
result set*DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ*

L5	l1 with l2 with l3 with L4	98	L5
L4	express or expression or expressed or expressing (cancer or tumor) with (inhibit or inhibition! or inhibited! or inhibiting!	593202	L4
L3	or reduce or reducing! or reduced! or reduction! or kill or killing! or killed!)	35203	L3
L2	(cancer or tumor) with (inhibit\$ or reduc\$ or kill\$)	38287	L2
L1	p53	131752	L1

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 50 of 98 returned.**

-
1. [20020077317](#). 15 Dec 00. 20 Jun 02. Method of potentating the action of 2-methoxyoestradiol, statins and C-peptide of proinsulin. Das, Undurti Narasimha. 514/171; 424/131.1 514/4 514/423 514/460 A61K038/28 A61K039/395 A61K031/56 A61K031/40 A61K031/35.
-
2. [20020077313](#). 01 Oct 01. 20 Jun 02. Methods and compositions for the diagnosis and treatment of cancer. Clayman, Gary L.. 514/44; 424/93.21 435/320.1 A61K048/00 C12N015/861.
-
3. [20020065213](#). 15 Jan 99. 30 May 02. METHODS AND COMPOSITIONS FOR NONVIRAL GENE DELIVERY. DEBS, ROBERT J.. 514/2; 435/352 435/366 435/455 435/69.1 514/12 514/44 514/8 530/383 A61K048/00 A61K038/17 C12P021/02 C12N005/06 C12N005/08 C12N015/87.
-
4. [20020064521](#). 22 Feb 01. 30 May 02. P53-specific T cell receptor for adoptive immunotherapy. Ellenhorn, Joshua D. I., et al. 424/93.21; 435/320.1 435/372 536/23.5 A61K048/00 C07H021/04 C12N005/08.
-
5. [20020061296](#). 10 Sep 01. 23 May 02. Delivery method for the tumor specific apoptosis inducing activity of apoptin. Noteborn, Mathieu H.M., et al. 424/93.21; 424/94.63 435/226 435/320.1 435/325 435/69.1 A61K048/00 A61K038/48 C12N009/64 C12P021/02 C12N015/867 C12N005/06.
-
6. [20020055174](#). 29 May 01. 09 May 02. Complex for transferring an anionic substance of interest into a cell. Rittner, Karola, et al. 435/463; 530/350 C12N015/87 C07K014/00.
-
7. [20020049180](#). 30 May 01. 25 Apr 02. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers. Wu, Bin, et al. 514/44; 424/155.1 A61K048/00 A61K039/395.
-
8. [20020048566](#). 13 Sep 01. 25 Apr 02. Modulation of cellular apoptosis and methods for treating cancer. El-Deiry, Wafik S., et al. 424/93.21; 435/320.1 514/12 A61K048/00 A61K038/17 C12N015/86.
-
9. [20020031763](#). 21 Jan 00. 14 Mar 02. CATIONIC POLYMERS, COMPLEXES ASSOCIATING SAID CATIONIC POLYMERS WITH THERAPEUTICALLY ACTIVE SUBSTANCES COMPRISING AT LEAST ONE NEGATIVE CHARGE, IN PARTICULAR NUCLEIC ACIDS, AND THEIR USE IN GENE THERAPY. KOLBE, HANNO V.J., et al. 435/6; 435/91.1 536/23.1 C12Q001/68 C07H021/02 C07H021/04 C12P019/34.
-
10. [20020031527](#). 28 Aug 01. 14 Mar 02. Formulation of adenovirus for gene therapy. Wu, Zheng, et al. 424/233.1; 424/93.21 A61K048/00 A61K039/235.
-
11. [20020028498](#). 30 May 01. 07 Mar 02. Recombinant MVA virus expressing the E2 gene of Bovine papillomavirus and its use in the therapy of tumors generated by papillomaviruses. Ledezma, Ricardo R.. 435/235.1; 424/204.1 530/350 536/72 C08B001/02 A61K039/12 C12N007/00 C12N007/01 C07K001/00 C07K014/00 C07K017/00.
-
12. [20020028202](#). 02 Apr 01. 07 Mar 02. Common gamma chain blocking agents. Burkly, Linda

C., et al. 424/143.1; 424/130.1 424/133.1 530/387.3 530/387.5 530/388.22 536/23.5 C07H021/04
A61K039/395 A61K039/40 A61K039/42 C12P021/08 C07K016/00.

┐ 13. 20020019051. 31 May 01. 14 Feb 02. Chimeric adenoviral vectors. Lusky, Monika, et al.
435/457; 435/235.1 C12N015/861 C12N007/01.

┐ 14. 20020019040. 27 Mar 01. 14 Feb 02. Apoptin-associating protein. Noteborn, Mathieu
Hubertus M., et al. 435/226; 424/93.21 435/366 514/44 536/23.2 A61K048/00 C07H021/04 C12N009/64
C12N005/08.

┐ 15. 20020013274. 22 May 01. 31 Jan 02. Methods for identifying inducers and inhibitors of
proteolytic antibodies, compositions and their uses. Paul, Sudhir, et al. 514/12; 424/155.1 435/188.5
A61K039/395 C12N009/00.

┐ 16. 20020012964. 19 Dec 00. 31 Jan 02. Cell cycle regulating factor. Nakanishi, Makoto. 435/69.1;
424/155.1 435/184 435/194 435/325 530/388.1 536/23.2 C12P021/02 C12N005/06 C07H021/04
A61K039/395 C12N009/99 C12N009/12.

┐ 17. 20020010144. 10 Jan 01. 24 Jan 02. Enhancing the sensitivity of tumor cells to therapies.
Sobol, Robert, et al. 514/44; A61K048/00.

┐ 18. 20020009455. 20 Apr 01. 24 Jan 02. DNA encoding a novel PROST 03 polypeptide. Lau, Ted,
et al. 424/178.1; 435/325 435/6 435/69.1 435/7.23 530/350 C12Q001/68 G01N033/574 C12P021/02
A61K039/395 C07K014/435.

┐ 19. 20020006914. 26 Jan 01. 17 Jan 02. Enhancing the sensitivity of tumor cells to therapies.
Sobol, Robert E., et al. 514/44; A61K048/00.

┐ 20. 20020006902. 24 Jan 01. 17 Jan 02. Combinations and methods for promoting in vivo liver
cell proliferation and enhancing in vivo liver-directed gene transduction. Alison, Malcolm R., et al. 514/12;
514/567 A61K038/18 A61K031/195.

┐ 21. 20020006663. 09 Mar 01. 17 Jan 02. p27 and p21 in gene therapies. Scadden, David T., et al.
435/455; 435/366 C12N015/85 C12N005/08.

┐ 22. 20020004047. 07 Dec 00. 10 Jan 02. DNA encoding a novel RG1 polypeptide. Harkins,
Richard, et al. 424/178.1; 435/325 435/6 435/69.1 435/7.23 530/388.8 C12Q001/68 G01N033/574
C12P021/02 A61K039/395.

┐ 23. 20010044651. 14 Dec 00. 22 Nov 01. Expandable stent with sliding and locking radial
elements. Steinke, Thomas A., et al. 623/1.16; 623/1.17 A61F002/06.

┐ 24. 20010016583. 22 Jan 01. 23 Aug 01. Therapeutic application of pro-apoptotic
benzodiazepines. Glick, Gary D., et al. 514/220; A61K031/5513.

┐ 25. 20010016192. 28 Oct 97. 23 Aug 01. RECOMBINANT ADENOVIRAL VECTOR AND
METHOD OF USE. GREGORY, RICHARD J., et al. 424/93.2; 424/93.6 435/320.1 435/455 435/456
435/69.1 A61K048/00 C12N015/861.

- └ 26. 20010006629. 24 Nov 99; 05 Jul 01. RECOMBINANT ADENOVIRAL VECTOR AND METHODS OF USE. GREGORY, RICHARD J., et al. 424/93.1; 424/93.2 424/93.6 435/320.1 514/44 A61K048/00 C12N015/861.
-
- └ 27. 6407178. 21 Jan 00; 18 Jun 02. Cationic polymers, complexes associating said cationic polymers with therapeutically active substances comprising at least a negative charge, in particular nucleic acids, and their use in gene therapy. Kolbe; Hanno V. J., et al. 525/328.2; 424/78.01 424/78.08. A01N043/04 A61K031/74 A61K039/245 C08F116/00.
-
- └ 28. 6399587. 02 Dec 99; 04 Jun 02. Recombinant adenoviral vectors comprising a splicing sequence. Mehtali; Majid, et al. 514/44; 424/93.2 435/320.1 435/325 435/455 536/23.1 536/24.1. A61K048/00 A61K035/00 C12N015/63 C12N015/85 C12N015/86 C07H021/04.
-
- └ 29. 6388062. 05 May 99; 14 May 02. Modified p53 tetramerization domains having hydrophobic amino acid substitutions. Halazonetis; Thanos D., et al. 536/23.4; 530/350 530/827 536/23.1 536/23.5. C07H021/02 C07H021/04 C07K001/00 C07K014/00.
-
- └ 30. 6376236. 22 Jan 99; 23 Apr 02. Recombinant alphavirus particles. Dubensky, Jr.; Thomas W., et al. 435/320.1; C12N015/63.
-
- └ 31. 6355622. 16 Feb 99; 12 Mar 02. Use of a melanoma differentiation associated gene (mda-7) for inducing apoptosis of a tumor cell. Fisher; Paul B.. 514/44; 435/6 435/69.1. A01N043/04 C12Q001/68 C12P021/06.
-
- └ 32. 6348352. 04 Dec 95; 19 Feb 02. Methods for selectively transducing pathologic mammalian cells using a tumor suppressor gene. Shepard; H. Michael, et al. 435/455; 424/93.2 435/320.1. C12N015/88.
-
- └ 33. 6342372. 08 Jul 99; 29 Jan 02. Eukaryotic layered vector initiation systems for production of recombinant proteins. Dubensky, Jr.; Thomas W., et al. 435/69.1; 435/455 536/23.2 536/23.72 536/24.1. C12N005/16 C12N015/11 C12N015/33.
-
- └ 34. 6323027. 10 Nov 98; 27 Nov 01. Common gamma chain monoclonal antibody blocking agents. Burkly; Linda C., et al. 435/334; 530/388.22. C12N005/28.
-
- └ 35. 6258791. 29 Nov 99; 10 Jul 01. Combination product for enhanced gene delivery comprising a hyaluronidase. Braun; Serge. 514/44; 424/93.2. A61K048/00.
-
- └ 36. 6251398. 13 Sep 99; 26 Jun 01. Materials and methods for intracellular transport and their uses. O'Hare; Peter Francis Joseph, et al. 424/186.1; 424/192.1 424/204.1 424/208.1 424/248.1 424/263.1 435/235.1 435/252.3 435/317.1 435/325 530/350 530/826 536/23.4. A61K039/00 C12N015/62 C07K019/00.
-
- └ 37. 6248725. 23 Feb 99; 19 Jun 01. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction. Alison; Malcom R., et al. 514/44; 424/198.1 424/199.1 424/9.1 424/9.2 435/320.1 435/455 435/456 800/8 800/9. A01N043/04 A61K031/70 C12N015/00 C12N015/09 C12N015/63.
-
- └ 38. 6245515. 21 Sep 99; 12 Jun 01. Sequence specific DNA binding p53. Vogelstein; Bert, et al.

435/6; 536/23.1 536/24.33 536/24.5 536/25.3. C12Q001/68 C07H021/00 C07H021/02 C07H021/04 C07H019/00.

┐ 39. 6235891. 31 Mar 99; 22 May 01. Glucocorticoid receptor agonist and decreased PP5. Honkanen; Richard E.. 536/24.5; 435/325 435/366 435/375 435/6 435/91.1 536/23.1 536/24.3. C12N015/00 C12Q001/68.

┐ 40. 6235714. 23 Mar 98; 22 May 01. Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses. Paul; Sudhir, et al. 514/12; 530/324 530/325 530/326 530/327 530/328 530/329. A61K038/00.

┐ 41. 6210939. 25 Oct 94; 03 Apr 01. Recombinant adenoviral vector and methods of use. Gregory; Richard J., et al. 435/456; 435/252.3 435/320.1 435/363 435/366 435/370 435/371. C12N005/10 C12N015/10 C12N015/63 C12N015/86.

┐ 42. 6204060. 31 Mar 97; 20 Mar 01. Viral vectors and line for gene therapy. Mehtali; Majid, et al. 435/456; 435/320.1 435/325 435/366 435/369 435/370. C12N015/86 C12N005/10 C12N015/63.

┐ 43. 6194191. 20 Nov 97; 27 Feb 01. Method for the production and purification of adenoviral vectors. Zhang; Shuyuan, et al. 435/239; 424/199.1 435/235.1 435/320.1. C12N007/02 C12N007/01.

┐ 44. 6153391. 05 Mar 98; 28 Nov 00. Interruption of binding of MDM2 and P53 protein and therapeutic application thereof. Picksley; Steven Michael, et al. 435/7.1; 514/12 514/13 514/14 514/15 514/16 514/17 530/317 530/324 530/325 530/326 530/328 530/329 530/330. G01N033/53.

┐ 45. 6143727. 05 Jun 95; 07 Nov 00. Specific expression vectors and methods of use. Roop; Dennis R., et al. 514/44; 435/320.1 435/371 435/375. A61K048/00 C12N015/10 C12N015/09.

┐ 46. 6133243. 22 Feb 96; 17 Oct 00. Liposomal-viral DNA complexes for treating disease. Kim; David. 514/44; 435/325 435/375. A61K048/00.

┐ 47. 6110744. 12 Nov 97; 29 Aug 00. Diminishing viral gene expression by promoter replacement. Fang; Bingliang, et al. 435/456; 435/320.1 536/23.1 536/23.5 536/23.7 536/23.72 536/24.1. C12N015/64 C12N015/34 C12N015/12.

┐ 48. 6086900. 24 Mar 98; 11 Jul 00. Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes. Draper; Rockford. 424/282.1; 435/320.1 435/357 435/358 435/367 435/372.2 435/372.3 435/455 514/2 514/44 530/350 530/387.1 536/23.1 536/23.4 536/23.5 536/23.7. A61K039/44 C12N005/10 C07K017/02.

┐ 49. 6069134. 17 Oct 97; 30 May 00. Methods and compositions comprising DNA damaging agents and p53. Roth; Jack A., et al. 514/44; 424/93.21 435/320.1 435/325 435/455 435/458 435/69.1. A61K048/00.

┐ 50. 6060317. 11 Aug 98; 09 May 00. Method of transducing mammalian cells, and products related thereto. Malech; Harry L.. 435/456; 435/304.1 435/320.1 435/325 530/350. C12N015/63 C07K014/78 C12M001/24.

[Generate Collection](#)[Print](#)**Search Results - Record(s) 51 through 98 of 98 returned.**

-
- ☐ 51. [6057298](#). 30 May 95; 02 May 00. Keratin K1 expression vectors and methods of use. Roop; Dennis R., et al. 514/44; 435/320.1 435/371 435/375. A61K048/00 C12N005/10 C12N015/09.
-
- ☐ 52. [6054467](#). 05 Jul 96; 25 Apr 00. Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis. Gjerset; Ruth A.. 514/309; 435/7.1 435/7.23 514/456 514/617 514/619. A01N043/42 A01N037/18 A61K031/47 A61K031/165.
-
- ☐ 53. [6051376](#). 30 Sep 94; 18 Apr 00. Uses of mda-6. Fisher; Paul B., et al. 435/6; 435/69.1 436/501 514/2 514/44. C12Q001/68.
-
- ☐ 54. [6030956](#). 23 Oct 97; 29 Feb 00. Combination gene therapy for human cancers. Boulikas; Teni. 514/44; 428/402.2 435/320.1 536/23.2 536/23.5 536/24.1. C12N015/00 A01N043/04 C07H021/04 B32B005/16.
-
- ☐ 55. [6028245](#). 25 Jun 98; 22 Feb 00. Transgenic animals overexpressing MDM2. Wasylyk; Bohdan, et al. 800/18; 435/440 435/455 800/13 800/14 800/3 800/8 800/9. C12N015/00.
-
- ☐ 56. [6017735](#). 22 Jan 98; 25 Jan 00. Materials and methods for intracellular transport and their uses. O'Hare; Peter Francis Joseph, et al. 435/69.7; 435/252.3 435/317.1 435/320.1 435/325 435/69.3 530/350 536/23.4 536/23.5. C12N015/09 C12N015/62 C12N005/10 C07K019/00.
-
- ☒ 57. [6017524](#). 13 Oct 92; 25 Jan 00. Inhibiting the growth p53 deficient tumor cells by administering the p53 gene. Roth; Jack A., et al. 424/93.2; 435/320.1 435/91.41 514/44. A61K048/00 C12N015/00.
-
- ☐ 58. [6015694](#). 16 Sep 97; 18 Jan 00. Method for stimulating an immune response utilizing recombinant alphavirus particles. Dubensky, Jr.; Thomas W., et al. 435/69.3; 424/199.1 424/204.1 424/228.1 424/234.1 424/265.1 424/274.1 424/277.1 536/23.5 536/23.7 536/23.72. C12P021/06.
-
- ☐ 59. [6015686](#). 15 Mar 95; 18 Jan 00. Eukaryotic layered vector initiation systems. Dubensky, Jr.; Thomas W., et al. 435/69.1; 435/320.1 435/325 435/410 435/455 435/456 536/23.5 536/23.72 536/24.1. C12P021/02 C12N015/00 C12N015/63 C12N015/11.
-
- ☐ 60. [6013786](#). 06 May 98; 11 Jan 00. MDM2-specific antisense oligonucleotides. Chen; Jiandong, et al. 536/24.5; 536/23.1 536/24.3 536/24.31. C07H021/04.
-
- ☐ 61. [5997869](#). 14 Sep 95; 07 Dec 99. Peptides containing a fusion joint of a chimeric protein encoded by DNA spanning a tumor-associated chromosomal translocation and their use as immunogens. Goletz; Theresa J., et al. 424/184.1; 424/185.1 424/192.1 530/300 530/326 530/327. A61K039/00 A61K038/00 A61K038/04.
-
- ☐ 62. [5981502](#). 07 Jun 95; 09 Nov 99. Methods and compositions for inducing apoptosis in tumor cells. Noteborn; Matheus Hubertus Maria, et al. 514/44; 435/7.23 514/12 514/2. A61K038/00 A01N043/04 A01N037/08 G01N033/574.

-
- ┐ 63. 5965539. 11 Jan 96; 12 Oct 99. Inhibitors of prenyl transferases. Sebti; Said, et al. 514/19; 530/331 562/557 562/559 564/336 564/337. A61K038/05.
-
- ┐ 64. 5962667. 03 Nov 97; 05 Oct 99. Pharmaco-gene delivery in human breast cancer cells. Jain; Pramod, et al. 536/23.1; 536/23.2 536/23.5 536/23.72 540/2. C12N015/12 C12N015/33 C07J001/00.
-
- ┐ 65. 5955263. 01 Sep 94; 21 Sep 99. Sequence specific DNA binding by p53. Vogelstein; Bert, et al. 435/6; 435/7.23 436/63 436/64 536/23.1 536/24.1. C12Q001/68 G01N033/574 G01N033/48 C07H021/02.
-
- ┐ 66. 5952195. 09 Mar 98; 14 Sep 99. Promoters for expressing proteins of interest in yeast. Nacken; Valerie, et al. 435/69.1; 435/320.1 435/440 435/69.2 435/69.3 435/69.4 435/69.5 435/69.6 435/69.9 536/23.1 536/24.1. C12P021/02 C07H021/04 C12N015/63.
-
- ┐ 67. 5932210. 28 Oct 97; 03 Aug 99. Recombinant adenoviral vector and methods of use. Gregory; Richard J., et al. 424/93.2; 424/93.6 435/320.1. A61K048/00 C12N015/86.
-
- ┐ 68. 5925565. 05 Mar 96; 20 Jul 99. Internal ribosome entry site, vector containing it and therapeutic use. Berlioz; Clarisse, et al. 435/325; 424/93.21 435/320.1 435/455 435/69.1 514/44 536/23.1 536/24.1. C12N015/00.
-
- ┐ 69. 5908750. 11 Apr 97; 01 Jun 99. Screening assays for identifying agents that regulate the expression of genes involved in cell death. Reed; John C., et al. 435/6; 435/29. C12Q001/68 C12Q001/02.
-
- ┐ 70. 5876972. 23 Sep 96; 02 Mar 99. Nucleic acid molecules coding for tumor suppressor proteins and methods for their isolation. Spengler; Dietmar, et al. 435/69.1; 435/252.3 435/320.1 435/325 435/410 435/6 536/23.5. C12P021/00 C12N015/12.
-
- ┐ 71. 5843723. 30 Oct 96; 01 Dec 98. Alphavirus vector constructs. Dubensky, Jr.; Thomas W., et al. 435/69.3; 435/235.1 435/320.1 435/325. C12P021/02 C12N015/63 C12N005/10.
-
- ┐ 72. 5840673. 12 Sep 96; 24 Nov 98. Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of p53-related tumors. Buckbinder; Leonard R., et al. 510/392; 510/226 510/320 510/321 510/393 510/530. A61K038/17 C12Q001/02.
-
- ┐ 73. 5834434. 30 May 95; 10 Nov 98. Inhibitors of farnesyltransferase. Sebti; Said M., et al. 514/19; 562/545 562/557 562/559. A61K038/05.
-
- ┐ 74. 5834237. 07 Oct 96; 10 Nov 98. Combined use of two expression cassettes for the production of a protein of interest. Jacobs; Eric, et al. 435/69.1; 435/254.11 435/254.21 536/23.1 536/24.1. C12P021/06.
-
- ┐ 75. 5814482. 30 Oct 96; 29 Sep 98. Eukaryotic layered vector initiation systems. Dubensky, Jr.; Thomas W., et al. 435/69.3; 435/320.1 536/23.1 536/24.1. C12P021/00 C12N015/86 C07H021/04.
-
- ┐ 76. 5789245. 30 Oct 96; 04 Aug 98. Alphavirus structural protein expression cassettes. Dubensky, Jr.; Thomas W., et al. 435/320.1; 435/325 435/69.1 536/23.72. C12N015/63 C12N015/40 C12N005/10 C12P021/02.
-

☐ 77. 5770377. 19 Apr 95; 23 Jun 98. Interruption of binding of MDM2 and P53 protein and therapeutic application thereof. Picksley; Steven Michael, et al. 435/7.1; 435/7.23 435/7.9 435/7.91 435/7.92 435/7.93 436/501 436/518 436/523 436/524 436/525 436/526 436/527 436/528 436/529 436/530 436/531 436/64 436/813. G01N033/53 G01N033/574 G01N033/542 G01N033/543.

☐ 78. 5747469. 25 Apr 94; 05 May 98. Methods and compositions comprising DNA damaging agents and p53. Roth; Jack A., et al. 514/44; 435/320.1 435/375 514/2. A61K048/00 C12N005/00 C12N015/00.

☐ 79. 5744310. 29 Jul 96; 28 Apr 98. Bax promoter sequence and screening assays for indentifying agents that regulate bax gene expression. Reed; John C.. 435/6; 435/325 435/69.1 435/91.4 536/24.1. C12Q001/68 C12P021/00 C12N005/10 C07H021/04.

☐ 80. 5726024. 10 May 96; 10 Mar 98. p53as protein and antibody therefor. Kulesz-Martin; Molly F.. 435/7.1; 435/7.23 530/387.7 530/388.8 530/388.85 530/389.7. G01N033/53 G01N033/577 C07K016/18 C07K016/30.

☐ 81. 5710137. 16 Aug 96; 20 Jan 98. Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype. Fisher; Paul B.. 514/44; 435/69.3 435/810 514/2. A61K048/00.

☐ 82. 5702908. 20 Jul 94; 30 Dec 97. Interruption of binding of MDM2 and p53 protein and therapeutic application thereof. Picksley; Steven Michael, et al. 435/7.8;. G01N033/53.

☒ 83. 5700657. 13 Dec 93; 23 Dec 97. Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby. Beaudry; Gary A., et al. 435/69.1; 435/235.1 435/325 435/91.33. C12P021/02 C12P019/34 C12N005/10 C12N007/01.

☐ 84. 5688918. 14 Jun 94; 18 Nov 97. p53as protein and antibody therefor. Kulesz-Martin; Molly F.. 530/387.7; 530/388.8 530/388.85 530/389.7. C07K016/18 C07K016/32 C12N005/12.

☐ 85. 5659024. 27 Oct 94; 19 Aug 97. Promoters that regulate the expression of genes involved in cell death. Reed; John C., et al. 536/24.1; 536/23.1. C07H021/04.

☐ 86. 5652115. 18 Jul 94; 29 Jul 97. Method of detecting tumors containing complexes of p53 and HSP70. Marks; Jeffrey Robert, et al. 435/7.23; 435/7.93 435/7.94 435/7.95 436/503 436/506 436/64 436/813. G01N033/574 G01N033/53.

☒ 87. 5484710. 14 Jan 94; 16 Jan 96. Method of down-regulating a gene linked to a P-53 responsive element. Reed; John C., et al. 435/69.1; 536/24.1. C12P021/00 C12N015/09.

☐ 88. 5362623. 31 Mar 92; 08 Nov 94. Sequence specific DNA binding by p53. Vogelstein; Bert, et al. 435/6; 435/320.1 536/24.1 536/24.31. C12Q001/68.

☐ 89. JP 09100289 A. 02 Oct 95. 15 Apr 97. NEW COMPOUND FR190895, FR190872 AND FR190873, THEIR PRODUCTION AND USE THEREOF. NAKAJIMA, SHUSUKE, et al. C07G017/00; A61K035/74 C12N015/09 C12P001/04 C12N001/20.

☐ 90. EP 1186665 A1, WO 200220809 A1. Use of a proteinaceous substance comprising apoptin or its functional equivalent or fragment for induction of tumor-specific apoptosis for treating cancer and

autoimmune diseases. LELIVELD, S R, et al. A61K038/16 C07K014/01 C07K014/16 C12N001/21 C12N015/34 C12N015/62 C12N015/87 G01N033/574.

91. AU 200039769 A, WO 200174403 A1. Combination of wild-type p53 gene and E1B-deleted p53 gene given simultaneously or sequentially to produce cytotoxic effect in human and animal cancer cells. WOOD, C B. A61K048/00 A61P035/00.

92. WO 200110883 A1. p53 apoptosis effector related to PMP-22 polypeptide and polynucleotide, used to stimulate apoptosis in cells, particularly tumor cells, and to antisense sequences used to inhibit the protein's expression. ATTARDI, L D, et al. C07H021/02 C07H021/04 C07K001/00 C07K014/00 C07K017/00.

93. US 6143727 A. Gene therapy of skin cancer involving administering specific expression vector, loricrin or K6 keratin expression vector within the epidermis or epidermal cells. GREENHALGH, D A, et al. A61K048/00 C12N015/09 C12N015/10.

94. US 6057298 A. Use of K-1 keratin expression vectors for treating skin cancer in mammals, comprises administering the vector at or directly around the site of a skin cancer cell resulting in expression of p53 protein. GREENHALGH, D A, et al. A61K048/00 C12N005/10 C12N015/09.

95. WO 9921583 A1, ZA 9809840 A, AU 9911107 A. Inhibiting metastases of cancer cells comprising administering matrix metalloproteinase-2 inhibitor useful for treating cancer. SUN, Y. A61K000/00 A61K041/00.

96. JP 2001516568 W, FR 2768346 A1, WO 9913908 A1, EP 1015029 A1. Compound that inhibits presenilin 1 gene expression or gene product activity - useful for diagnosis and treatment of cancer and Alzheimer's disease. AMSON, R, et al. A61K031/70 A61K039/395 A61K048/00 A61P035/00 A61P043/00 C07K014/47 C07K016/18 C12N015/09 C12N015/11 C12P021/08 C12Q001/68 G01N033/574 G01N033/577 C07K014/47 C07K016:18 C12N015:11.

97. US 5858976 A. Inhibiting growth of tumour cells having MDM2 gene amplification - with MDM2-binding p53 fragment. KINZLER, K W, et al. C07K014/435.

98. JP 2000502893 W, WO 9722695 A2, FR 2742766 A1, FR 2747691 A1, WO 9722695 A3, EP 868512 A2. New genes activated or inhibited during apoptosis - useful for treatment of, and for assessing risk of developing, cancer and Alzheimer's disease. AMSON, R, et al. A61K038/00 A61K038/17 A61K039/395 A61K045/00 A61K048/00 A61P025/28 A61P035/00 C07K014/435 C07K014/46 C07K014/47 C07K014/82 C07K016/32 C12N005/10 C12N015/02 C12N015/09 C12N015/12 C12N015/70 C12N015/74 C12N015/79 C12N015/86 C12P021/08 C12Q001/68 G01N033/53 G01N033/574 G01N033/68 C12N015/09 C12N015/09 C12R001:91 C12R001:92.

Generate Collection

Print

Terms	Documents
I1 with I2 with I3 with I4	98

[Previous Page](#)

[Next Page](#)

Generate Collection

Print

Search Results - Record(s) 1 through 11 of 11 returned.

-
1. 20010023077. 12 Apr 01. 20 Sep 01. Method and apparatus for measurement of binding between a protein and a nucleotide. Erb, Judith L., et al. 436/518; G01N033/543.
-
2. 6407062. 07 Jan 00; 18 Jun 02. ARF-P19, a novel regulator of the mammalian cell cycle. Sherr; Charles J., et al. 514/12; 530/300 530/324 530/325 530/326 530/327 530/328 530/329 530/330 530/350. C07K014/00.
-
3. 6251688. 20 Mar 98; 26 Jun 01. Method and apparatus for measurement of binding between a protein and a nucleotide. Erb; Judith L., et al. 436/518; 385/12 385/123 385/129 385/130 385/15 385/25 422/55 422/57 422/82.05 422/82.08 422/82.11 435/287.1 435/287.2 435/287.9 435/288.7 435/6 435/7.9 435/808 436/164 436/172 436/510 436/524 436/527 436/65 436/805 436/814 436/817 436/818. G01N033/543.
-
4. 6245886. 04 Dec 97; 12 Jun 01. Peptides and peptidomimetics with structural similarity to human P53 that activate P53 function. Halazonetis; Thanos, et al. 530/332; 530/323. A61K038/00.
-
5. 6169073. 16 Feb 95; 02 Jan 01. Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function. Halazonetis; Thanos, et al. 514/12; 530/300 530/317 530/323 530/324. A61K038/00.
-
6. 6147056. 26 Mar 98; 14 Nov 00. Use of locally applied DNA fragments. Gilchrest; Barbara A., et al. 514/44; 424/450 514/43 514/45 514/46 514/47. A61K048/00 A61K009/127 A61K031/70.
-
7. 6069134. 17 Oct 97; 30 May 00. Methods and compositions comprising DNA damaging agents and p53. Roth; Jack A., et al. 514/44; 424/93.21 435/320.1 435/325 435/455 435/458 435/69.1. A61K048/00.
-
8. 6030956. 23 Oct 97; 29 Feb 00. Combination gene therapy for human cancers. Boulikas; Teni. 514/44; 428/402.2 435/320.1 536/23.2 536/23.5 536/24.1. C12N015/00 A01N043/04 C07H021/04 B32B005/16.
-
9. 6013786. 06 May 98; 11 Jan 00. MDM2-specific antisense oligonucleotides. Chen; Jiandong, et al. 536/24.5; 536/23.1 536/24.3 536/24.31. C07H021/04.
-
10. 5747469. 25 Apr 94; 05 May 98. Methods and compositions comprising DNA damaging agents and p53. Roth; Jack A., et al. 514/44; 435/320.1 435/375 514/2. A61K048/00 C12N005/00 C12N015/00.
-
11. JP 2000516207 W, WO 9801123 A1, AU 9736705 A, EP 910357 A1, US 6054467 A, AU 724212 B. Inducing p53-mediated apoptosis by treatment with an agent that inhibits DNA repair - for treatment of cancers, optionally in combination with p53 gene therapy or with DNA damaging agents. GJERSET, R A. A01N037/18 A01N043/42 A61K031/165 A61K031/166 A61K031/20 A61K031/203 A61K031/47 A61K031/70 A61K031/71 A61K033/24 A61K045/00 A61P035/00.
-

[Generate Collection](#)[Print](#)

Terms	Documents
l1 with l2 with l3 with l4	11

[Previous Page](#)[Next Page](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 18 of 18 returned.**

-
1. 20020049180. 30 May 01. 25 Apr 02. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers. Wu, Bin, et al. 514/44; 424/155.1 A61K048/00 A61K039/395.
-
2. 20020019425. 06 Sep 01. 14 Feb 02. p53 Inhibitors and therapeutic use of the same. Gudkov, Andrei V., et al. 514/366; 514/375 514/386 514/393 A61K031/429 A61K031/424 A61K031/4188.
-
3. 20020013274. 22 May 01. 31 Jan 02. Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses. Paul, Sudhir, et al. 514/12; 424/155.1 435/188.5 A61K039/395 C12N009/00.
-
4. 20020006941. 13 Jun 01. 17 Jan 02. p53 inhibitors and therapeutic use of the same. Gudkov, Andrei V., et al. 514/366; 514/375 A61K031/429 A61K031/424.
-
5. 20020006902. 24 Jan 01. 17 Jan 02. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction. Alison, Malcolm R., et al. 514/12; 514/567 A61K038/18 A61K031/195.
-
6. 20010011076. 20 Aug 98. 02 Aug 01. COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCERS. SCHWARTZ, GARY K., et al. 514/44; 424/94.1 435/325 435/375 435/455 435/6 435/91.1 A61K048/00 C12N015/85 C12N015/86 A61K038/43 C12P019/34.
-
7. 6372424. 30 Aug 95; 16 Apr 02. Rapid detection and identification of pathogens. Brow; Mary Ann D., et al. 435/5; 435/6 435/69.1 435/91.2 536/24.3. C12Q001/70 C12Q001/68 C12Q021/00 C07H021/04.
-
8. 6303328. 10 Mar 99; 16 Oct 01. Inhibition of cellular proliferation in vitro by oligonucleotide binding to a chromosomal binding site for p53 protein. Re; Richard, et al. 435/29; 435/325 435/455 536/24.5. C12Q001/02 C12N005/00 C12N015/00.
-
9. 6248725. 23 Feb 99; 19 Jun 01. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction. Alison; Malcom R., et al. 514/44; 424/198.1 424/199.1 424/9.1 424/9.2 435/320.1 435/455 435/456 800/8 800/9. A01N043/04 A61K031/70 C12N015/00 C12N015/09 C12N015/63.
-
10. 6235714. 23 Mar 98; 22 May 01. Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses. Paul; Sudhir, et al. 514/12; 530/324 530/325 530/326 530/327 530/328 530/329. A61K038/00.
-
11. 6028245. 25 Jun 98; 22 Feb 00. Transgenic animals overexpressing MDM2. Wasylyk; Bohdan, et al. 800/18; 435/440 435/455 800/13 800/14 800/3 800/8 800/9. C12N015/00.
-
12. 5985829. 01 Jul 96; 16 Nov 99. Screening assays for compounds that cause apoptosis and

related compounds. Harris; Curtis C., et al. 514/12; 514/13 514/14 514/15 530/324 530/326 530/328.
A61K038/08 A61K038/16 C07K007/06 C07K014/00.

└ 13. 5936079. 15 Aug 94; 10 Aug 99. Oligonucleotide which binds to a chromosomal binding site for p53 protein. Re; Richard, et al. 536/24.5; 435/455. C07H021/04 A61K048/00 C12N005/01.

└ 14. 5843669. 29 Nov 96; 01 Dec 98. Cleavage of nucleic acid acid using thermostable methoanococcus jannaschii FEN-1 endonucleases. Kaiser; Michael W., et al. 435/6; 435/18 435/183 435/194 435/195 435/196 435/4 435/810 435/822 435/91.53 436/94 530/350. C12Q001/68 C12P019/34 C12N009/12 C12N001/00.

└ 15. 5843654. 07 Jun 95; 01 Dec 98. Rapid detection of mutations in the p53 gene. Heisler; Laura M., et al. 435/6; 435/194 435/91.1. C12Q001/68 C12P019/34.

└ 16. 5821072. 20 Feb 96; 13 Oct 98. Combinations of PKC inhibitors and therapaeutic agents for treating cancers. Schwartz; Gary K., et al. 435/15; 424/9.2 435/193 435/194 435/7.1 435/7.23. C12Q001/48 C12N009/10.

└ 17. US 2002019425 A1, WO 200044364 A2, AU 200035842 A, EP 1143943 A2, US 2002006941 A1. New method of treating a disease or condition in which inhibition of p53 activity provides a benefit comprising administration of a temporary p53 inhibitor.. GUDKOV, A V, et al. A61K031/00 A61K031/4188 A61K031/424 A61K031/429.

└ 18. WO 9613266 A1, AU 9641398 A, ZA 9509119 A, NO 9701929 A, FI 9701746 A, EP 788360 A1, TW 318850 A, KR 97706824 A, JP 10510245 W, AU 710564 B, MX 9703063 A1, NZ 296717 A, US 6083903 A, NZ 337211 A, NO 310558 B1, CN 1168633 A. Acyl-amino-boronic acids, and related peptide (mimetics) - are proteasome inhibitors, use to reduce muscle breakdown, cyclin degradation, cancer cell, antigen, and NF-kappaB activity, used e.g. in HIV. ADAMS, J, et al. A61K000/00 A61K031/185 A61K031/395 A61K031/40 A61K031/47 A61K031/535 A61K031/69 A61K038/00 A61K038/55 C07C000/00 C07C229/02 C07C229/26 C07D207/16 C07D213/30 C07D215/12 C07D215/36 C07D215/48 C07D241/12 C07D295/14 C07D295/18 C07D307/68 C07D401/12 C07D471/04 C07F000/00 C07F005/02 C07F005/04 C07K005/062 C07K005/065 C07K005/078 C07K005/083.

Generate Collection

Print

Terms	Documents
L8 not 15	18

[Previous Page](#)

[Next Page](#)